Service
Architecture review before implementation
Implementation scope and rollout planning
Clear next-step recommendation
Accelerate lead identification from years to weeks with an end-to-end computational platform integrating generative AI and molecular simulation.
Traditional drug discovery is a $2.6B, 10+ year gamble. Our platforms compress this timeline by integrating:
AlphaFold, Schrödinger) for binding affinity prediction.Reduce preclinical candidate identification from 18-24 months to 8-12 weeks while cutting computational screening costs by 70%.
We architect secure, scalable platforms that ensure IP protection and regulatory readiness (FDA/EMA). Move from hypothesis-driven to AI-driven discovery. Explore our related service for foundational model strategy: Bio-AI Foundation Model Consulting.
Key Deliverables:
For specialized adaptation of models to your specific disease context, see our Computational Biology Model Fine-tuning service.
Our platform development focuses on accelerating timelines and de-risking investments. We architect systems that deliver quantifiable improvements across the discovery pipeline, from target identification to lead optimization.
Integrate generative AI for de novo molecule design with molecular simulation to rapidly generate and prioritize high-quality candidates, compressing discovery cycles from months to weeks.
Deploy custom-trained models on proprietary assay data to improve binding affinity and ADMET property predictions, reducing costly late-stage attrition by focusing resources on the most promising candidates.
Engineer robust MLOps pipelines for heterogeneous biological data (omics, HTS, literature), ensuring data integrity, reproducibility, and seamless integration with existing lab informatics systems. Learn about our approach to Bio-AI Data Pipeline and MLOps Engineering.
Build with compliance by design. Our platforms include embedded tracking for data lineage, model versioning, and performance validation, creating the documentation foundation required for FDA/EMA submissions.
Shift experimental focus from low-probability screening to high-confidence validation. AI-driven triage reduces wet-lab resource consumption on poor candidates, directly lowering operational costs.
Orchestrate specialized AI agents for target analysis, literature mining, and synthetic route planning into a cohesive discovery workflow, automating complex, multi-step research tasks. Explore our capabilities in Agentic Workflow Design and Integration.
Compare the total cost, risk, and time-to-market of building an AI-driven drug discovery platform in-house versus partnering with Inference Systems for a custom, production-ready solution.
| Capability / Specification | Build In-House | Inference Systems Platform |
|---|---|---|
Time to First Validated Lead | 9-18 months | 4-8 weeks |
Initial Architecture & Development Cost | $300K - $800K+ | $150K - $400K |
Core AI Model Stack | Open-source (ESM, AlphaFold) or costly API | Pre-integrated, fine-tuned models (ESM-3, proprietary GNNs) |
High-Throughput Screening Data Integration | Custom pipeline development required | Pre-built connectors for major HTS vendors |
Generative Molecule Design Module | Requires significant R&D | Included with iterative feedback loop |
Lab Automation & Closed-Loop Integration | Complex robotics API development | Pre-configured integration for common lab hardware |
Security & Compliance (FDA 21 CFR Part 11, HIPAA) | Your team's responsibility | Built-in audit trails, data integrity controls |
Ongoing MLOps & Model Maintenance | Dedicated 2-3 person team | Managed service with 99.9% uptime SLA |
Expertise Required | PhD-level computational biologists, ML engineers, DevOps | Dedicated project team with proven domain experience |
Total Cost of Ownership (Year 1) | $500K - $1.2M+ | $200K - $600K (predictable subscription) |
We architect AI-driven drug discovery platforms through a rigorous, phase-gated process designed to de-risk investment, accelerate time-to-market, and deliver lab-validated results. Our approach integrates deep computational biology expertise with enterprise-grade MLOps from day one.
We conduct a deep-dive technical assessment of your target pipeline, existing data assets, and scientific objectives. We define the optimal AI architecture—selecting between generative models, GNNs, or fine-tuned foundation models like ESM—and establish success metrics tied to wet-lab validation.
Learn more about our strategic approach in our Bio-AI Foundation Model Consulting service.
We build robust, scalable MLOps pipelines to ingest, featurize, and manage your heterogeneous biological data (omics, HTS, literature). This includes implementing synthetic data generation where needed and ensuring full data lineage for regulatory compliance.
This phase is critical for success, as detailed in our Bio-AI Data Pipeline and MLOps Engineering offering.
Our team develops and integrates the core AI models—customizing generative algorithms for molecular design, fine-tuning structure prediction models like AlphaFold for your targets, or implementing GNNs for pathway analysis. We prioritize explainability and integration with existing scientific software.
We engineer the full-stack application that unifies data, models, and simulation tools into a cohesive platform for your scientists. This includes intuitive interfaces for experiment design, result visualization, and collaborative analysis, built with security and scalability as first principles.
We rigorously validate model predictions against internal or public benchmarks and design pilot wet-lab experiments. The platform is then deployed into your secure cloud or on-premises environment with full monitoring, logging, and model retraining pipelines activated.
Ensuring regulatory readiness is key, as outlined in our Bio-AI Regulatory Compliance and Validation service.
We provide ongoing support to iteratively improve the platform based on new data and experimental feedback. This includes model retraining, feature expansion, and performance tuning to ensure the platform evolves as a core competitive asset in your R&D lifecycle.
Enabling Efficiency, Speed & Accuracy
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Common questions from CTOs and R&D leaders evaluating partners for building AI-driven drug discovery platforms. We provide specific, transparent answers based on our experience delivering validated computational biology solutions.
We follow a phased, milestone-driven approach. Phase 1 (2-3 weeks) involves a technical deep dive to define scope, data architecture, and select core models (e.g., fine-tuning ESM or AlphaFold). Phase 2 is iterative development with bi-weekly sprints, integrating components like generative molecular design, simulation, and lab data feedback loops. All projects include a final validation phase against your internal benchmarks. We assign a dedicated technical lead and provide full access to a shared project dashboard.
About the author
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
How We Work
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
The first call is a practical review of your use case and the right next step.
